Novavax (NVAX) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
682.2M
Gross Profit
479.4M
70.28%
Operating Income
-248.9M
-36.49%
Net Income
-187.5M
-27.49%
EPS (Diluted)
-$1.23
Balance Sheet Metrics
Total Assets
1.6B
Total Liabilities
2.2B
Shareholders Equity
-623.8M
Cash Flow Metrics
Operating Cash Flow
-60.4M
Free Cash Flow
-101.9M
Revenue & Profitability Trend
Novavax Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 682.2M | 556.4M | 1.6B | 197.6M | 22.4M |
| Cost of Goods Sold | 202.7M | 343.8M | 902.6M | 0 | 0 |
| Gross Profit | 479.4M | 212.6M | 696.3M | 197.6M | 22.4M |
| Operating Expenses | 728.4M | 779.1M | 1.3B | 1.9B | 439.1M |
| Operating Income | -248.9M | -566.5M | -644.7M | -1.7B | -416.7M |
| Pre-tax Income | -176.6M | -543.0M | -653.6M | -1.7B | -418.3M |
| Income Tax | 10.9M | 2.0M | 4.3M | 29.2M | 0 |
| Net Income | -187.5M | -545.1M | -657.9M | -1.7B | -418.3M |
| EPS (Diluted) | -$1.23 | -$5.41 | -$8.42 | -$23.44 | -$7.27 |
Income Statement Trend
Novavax Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 1.1B | 1.1B | 1.7B | 2.2B | 1.2B |
| Non-Current Assets | 431.5M | 653.6M | 555.3M | 421.6M | 334.3M |
| Total Assets | 1.6B | 1.8B | 2.3B | 2.6B | 1.6B |
| Liabilities | |||||
| Current Liabilities | 1.2B | 1.6B | 2.5B | 2.4B | 579.7M |
| Non-Current Liabilities | 1.0B | 879.3M | 432.8M | 538.1M | 375.6M |
| Total Liabilities | 2.2B | 2.5B | 2.9B | 2.9B | 955.3M |
| Equity | |||||
| Total Shareholders Equity | -623.8M | -716.9M | -634.1M | -351.7M | 627.2M |
Balance Sheet Composition
Novavax Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -187.5M | -545.1M | -657.9M | -1.7B | -418.3M |
| Operating Cash Flow | -60.4M | -796.2M | -863.5M | 322.9M | -42.5M |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Investing Cash Flow | -189.4M | 0 | 0 | 157.6M | -323.2M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 259.3M | 4.3M | 325.6M | 437.0M | 940.3M |
| Free Cash Flow | -101.9M | -772.8M | -508.9M | 265.5M | -97.2M |
Cash Flow Trend
Novavax Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
2.29
Forward P/E
-39.44
Price to Book
-13.82
Price to Sales
0.81
PEG Ratio
-39.44
Profitability Ratios
Profit Margin
38.14%
Operating Margin
77.40%
Return on Equity
30.06%
Return on Assets
19.97%
Financial Health
Current Ratio
2.06
Debt to Equity
-3.02
Beta
2.77
Per Share Data
EPS (TTM)
$2.75
Book Value per Share
-$0.47
Revenue per Share
$7.97
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| nvax | 1.0B | 2.29 | -13.82 | 30.06% | 38.14% | -3.02 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Vera Therapeutics | 1.4B | -8.41 | 2.58 | -39.49% | 0.00% | 10.18 |
| Immunocore Holdings | 1.6B | -31.41 | 4.13 | -5.86% | -6.48% | 114.67 |
| Agios | 1.9B | 2.89 | 1.32 | 60.26% | 1,798.26% | 3.61 |
Financial data is updated regularly. All figures are in the company's reporting currency.